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Abstract 
A broad spectrum of human diseases are caused by mutations in the NADPH cytochrome P450 
oxidoreductase (POR). Cytochrome P450 proteins perform several reactions, including the metabolism 
of steroids, drugs, and other xenobiotics. In 2004 the first human patients with defects in POR were 
reported, and over 250 variations in POR are known. Information about the effects of POR variants on 
drug metabolizing enzymes is limited and has not received much attention. By analyzing the POR 
sequences from genomics databases, we identified potentially disease-causing variations and 
characterized these by in vitro functional studies using recombinant proteins. Proteins were expressed 
in bacteria and purified for activity assays. Activities of cytochrome P450 enzymes were tested in vitro 
using liposomes prepared with lipids into which P450 and P450 reductase proteins were embedded. 
Here we are reporting the effect of POR variants on drug metabolizing enzymes CYP2C9, CYP2C19, 
and CYP3A5 which are responsible for the metabolism of many drugs. POR Variants A115V, T142A, 
A281T, P284L, A287P, and Y607C inhibited activities of all P450 proteins tested. Interestingly, the POR 
variant Q153R showed a reduction of 20-50% activities with CYP2C9 and CYP2C19 but had a 400% 
increased activity with CYP3A5. The A287P is most common POR mutation found in patients of 
European origin, and significantly inhibited drug metabolism activities which has important 
consequences for monitoring and treatment of patients. In vitro, functional assays using recombinant 
proteins provide a useful model for establishing the metabolic effect of genetic mutations. Our results 
indicate that detailed knowledge about POR variants is necessary for correct diagnosis and treatment 
options for persons with POR deficiency and the role of changes in drug metabolism and toxicology due 
to variations in POR needs to be addressed.  
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Introduction 
Cytochromes P450 proteins belong to heme-thiolate monooxygenase family and catalyze the 
conversion of many drugs and xenobiotics into the corresponding hydroxylated metabolites [1]. 
There are two types of cytochrome P450 in humans, type I (located in mitochondria), which 
participate in the biosynthesis of steroids, sterols, and retinoids and rely on ferredoxin 
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
1
4
6
6
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
2 
 
reductase and ferredoxin as their redox partners [2,3]. The type 2  cytochromes P450 (located 
in the endoplasmic reticulum) participate in the metabolism of drugs and xenobiotics and rely 
on reduced nicotinamide adenine dinucleotide phosphate (NADPH) for the supply of redox 
equivalents via NADPH cytochrome P450 oxidoreductase (POR) [4,5,6]. POR is a flavoprotein 
which is essential in drug metabolism due to its role as an obligatory redox partner for all 
cytochrome P450 proteins located in the endoplasmic reticulum [4]. POR has flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) domains that are connected by a flexible 
hinge region (residues 235 to 247) and electrons are transferred from NADPH through FAD 
hydroquinone to the isoalloxazine ring of FMN which then transfers it one at a time to the redox 
partners like cytochromes P450 [4,7,8,9,10,11] (Figure 1).  
  
 
 
Figure 1: POR and location of variants studied. A. Role of POR in the metabolism of drugs by cytochromes P450 
CYP2C9, CYP2C19, CYP3A5. POR supplies redox equivalents from NADPH to its redox partners via FAD and 
FMN co-factors. POR is the redox partner for cytochrome P450 proteins located in the endoplasmic reticulum, 
including the drug metabolizing enzymes CYP2C9, CYP2C19 and CYP3A5. A variety of drugs are metabolized 
by the three cytochrome P450 proteins tested in this study. Of note is the metabolism of warfarin and diclofenac 
by CYP2C9, metabolism of omeprazole, imipramine, proguanil, and diazepam by CYP2C19 and metabolism of 
renal transplant drug tacrolimus by CYP3A5. B: Location of variants studied. The model based on the x-ray crystal 
structure of the human POR (PDB#3QE2) showing the location of mutations studied in this report. The co-factors 
FMN, FAD, and NADP are shown as sticks. The mutation T142A is located next to the FMN binding site of POR, 
and its mutation would affect FMN binding. The Q153 residue is located at the surface of POR and predicted to 
have a role in the interactions with the redox partners. The A281, P284 and A287 residues are located in the hinge 
region of the POR. The hinge region of provides conformational flexibility, and mutations in the hinge region would 
result in conformational changes that would alter the interaction of POR with its redox partners. 
 
 
Cytochrome P450 oxidoreductase deficiency (PORD) is a rare form of congenital 
adrenal hyperplasia (CAH) [12,13]. PORD causes defects of adrenal steroidogenesis in 
addition to several other symptoms [14,15,16,17,18,19,20,21]. Likewise, many other alterations 
in enzymes activities from mutations in POR has been observed due to the multiplicity of its 
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redox partners, including heme oxygenase, CYP17A1,  CYP19A1, and CYP3A4 
[13,22,23,24,25,26,27,28,29]. Sequencing and biochemical studies have revealed many 
diseases caused by mutations in the POR gene [27,30,31,32]. These findings highlight the 
importance of POR variant studies on the enzymatic activity of different POR redox partners, 
especially the drug metabolizing enzymes.  The cytochrome P450 CYP2C9 metabolizes 
approximately 15% of clinically relevant drugs, including warfarin, diclofenac, and losartan 
[33,34]. CYP2C19 is involved in approximately 2% of the clinical drug metabolism, such as 
anticonvulsant drugs like certain barbiturates [35,36,37].  Cytochrome P450 3A5 belongs to the 
subfamily 3 of human cytochrome P450 proteins, and along with CYP3A4, it is one of the most 
promiscuous enzymes. The CYP3A5 has a role in extrahepatic tissues, especially in intestine 
and gut [38,39]. CYP3A5 expression varies between ethnic groups due to an allele that leads 
to an incorrectly spliced mRNA and premature termination of translation. CYP3A5 is involved 
in tacrolimus pharmacokinetics and influences the rate of tacrolimus clearance, which is of 
importance in organ transplant [40].   
 
We have been studying the variations in human POR genes since its link to disorders 
of steroid biosynthesis was discovered in 2004 [15,16,17,22,23,24,25,26,27,41,42,43]. These 
studies provided the background for exploring the effects of POR variations on different drug-
metabolizing cytochrome P450 enzymes. In this study, we have investigated the effects on the 
activity of three important drug metabolizing cytochrome P450s, CYP2C9, CYP2C19 and 
CYP3A5 by potentially disease-causing variations of the POR gene identified from genome 
sequencing projects [12,13,32]. 
 
 
Materials and Methods 
 
 
Recombinant expression of POR and Membrane purification: The human POR WT and 
variant forms of proteins (NCBI# NP_000932, Uniprot#  P16435) were recombinantly 
expressed in bacteria using the previously described methods and expression constructs 
[24,26,27,44]. The protocol for expression of an N-27 form of POR variants and subsequent 
membrane purification have been described and adopted from our previous publications 
[23,26,27,28,29].  
 
Western blot analysis of POR content in the bacterial membranes: For Western blots, 1 
μg of POR-WT and mutant membrane proteins were separated on an SDS-PAGE gel and 
blotted on to polyvinyl difluoride (PVDF) membranes to probe with a rabbit polyclonal antibody 
against wild-type human POR from Genscript (Genscript, NJ, USA) as described previously 
[43]. In all experiments described in this report, the normalized amount of POR content was 
used for the mutants as well as WT POR protein. 
 
Assay of cytochrome P450 CYP2C9 activity in reconstituted liposomes: The activity of 
CYP2C9 promoted by WT or mutant POR was tested using the fluorogenic substrate BOMCC 
(Invitrogen Corp, Carlsbad, CA, United States). The purified CYP2C9 (CYPEX, Dundee, 
Scotland, United Kingdom) was used to test the activities of the POR variants using 20 µM 
BOMCC as substrate. In vitro CYP2C9 assays were performed using a reconstituted liposome 
system consisting of WT/mutant POR, CYP2C9 and cytochrome b5 at a ratio of 5:1:1. The final 
assay mixture consisted of 5 µg DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) and 
proteins (1 µM POR: 200 nM CYP2C9: 200 nM b5), 3 mM MgCl2, 20 µM BOMCC in 100 mM 
Tris-HCl buffer pH 7.4 and the reaction volume was 100 µL. The P450 reaction was started by 
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addition of NADPH to a final concentration of 1 mM, and fluorescence was measured on a 
Spectramax M2e plate reader (Molecular Devices, Sunnyvale, CA, United States) at an 
excitation wavelength of 415 nm and an emission wavelength of 460 nm for BOMCC. 
 
 
 
Table 1: Frequencies of POR variants from NCBI Exome database. 
 
 
Assay of cytochrome P450 CYP2C19 activity in reconstituted liposomes: The activity of 
CYP2C19 promoted by WT or mutant POR was tested using the fluorogenic substrate EOMCC 
(Invitrogen Corp, Carlsbad, CA, United States). The purified CYP2C19 (CYPEX, Dundee, 
Scotland, United Kingdom) was used to test the activities of the POR variants using 20 µM 
EOMCC as substrate. In vitro CYP2C19 assays were performed using a reconstituted liposome 
system consisting of WT/mutant POR, CYP2C9 and cytochrome b5 at a ratio of 5:1:1. The final 
assay mixture consisted of 2.5 µg DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) and 
proteins (0.5 µM POR: 100 nM CYP2C9: 100 nM b5), 3 mM MgCl2, 20 µM EOMCC in 100 mM 
Tris-HCl buffer pH 7.4 and the reaction volume was 100 µL. The P450 reaction was started by 
addition of NADPH to a final concentration of 0.5 mM, and fluorescence was measured on a 
Spectramax M2e plate reader (Molecular Devices, Sunnyvale, CA, United States). 
 
Assay of cytochrome P450 CYP3A5 activity in reconstituted liposomes: The activity of 
CYP3A5 promoted by WT or mutant POR was tested using the fluorogenic substrate BOMCC 
(Invitrogen Corp, Carlsbad, CA, United States). The purified CYP3A5 (CYPEX, Dundee, 
Scotland, United Kingdom) was used to test the activities of the POR variants using 20 µM 
BOMCC as substrate. In vitro CYP3A5 assays were performed using a reconstituted liposome 
system consisting of WT/mutant POR, CYP3A5 and cytochrome b5 at a ratio of 5:1:1. The final 
assay mixture consisted of 5 µg DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) and 
proteins (1 µM POR: 200 nM CYP2C9: 200 nM b5), 3 mM MgCl2, 20 µM BOMCC in 100 mM 
Tris-HCl buffer pH 7.4 and the reaction volume was 100 µL. The CYP3A5 reaction was started 
by addition of NADPH to 1 mM final concentration, and fluorescence was measured on a 
Spectramax M2e plate reader (Molecular Devices, Sunnyvale, CA, United States) at an 
excitation wavelength of 415 nm and an emission wavelength of 460 nm for BOMCC. 
 
Protein structure analysis of POR variants: Three-dimensional structural models of POR 
(NCBI# NP_000932) proteins were obtained from the protein structure database 
(www.rcsb.org). We used the structures of the human POR (PDB # 3QE2) to analyze the 
POR DBSNP id 
 
Global European Asian American African 
A115V rs199634961 T=0.00020 T=0.00028 T=0.0002 T=0.0000 T=0.0001 
T142A rs1304915832 G=0.00000 G=0.00001 G=0.0000 G=0.0001 G=0.0002 
Q153R -   -  -  -  - -  
A281T  -  - -   -  -  - 
P284L rs72557938 T=0.00005 T=0.00004 T=0.0001 T=0.0000 T=0.0000 
A287P rs121912974 C=0.00024 C=0.00040 C=0.0000 C=0.0000 C=0.0001 
Y607C rs72557954 G=0.00011 G=0.00008 G=0.0003 G=0.0000 G=0.0000 
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location of amino acids described in this report [8]. Structure models were drawn using the 
software Pymol (www.pymol.org), and rendering of images was performed with POVRAY 
(www.povray.org). 
 
Statistical Analysis of results: Data are shown as mean, standard errors of the mean (SEM) 
in each group of replicates. Differences within the subsets of experiments were calculated using 
Student’s t-test. P values less than 0.05 were considered statistically significant. 
 
 
Results 
  
Sequence conservation and genetic distribution of POR variants: The POR variants 
studied in this report have been identified by mining the genome databases and performing 
structural stability and sequence conservation analysis to find out which of the variants may be 
potentially disease-causing [13]. Human POR is a 680 amino acid protein which has evolved 
from ferredoxin and ferredoxin reductase-like domains to form a single redox protein in 
eukaryotes.  All variations in POR studied here are highly conserved across species and are 
found as rare variants in NCBI Exome database (Table 1). The A115V was found mainly in 
European samples while T142 is a rare variant identified in the American population. The 
P284L is also a rare variant of predominantly European origin while the A287P is the most 
common pathogenic variant of POR seen in patients of European origin. The Y607C is rare 
variant seen in European and Asian populations. 
 
 
 
Figure 2: CYP2C9 activity promoted by WT and variants of POR proteins. Activity with the WT POR was set at a 
hundred percent, and results are given as a percentage of the activity supported by WT POR. In CYP2C9 assays 
POR variants A115V, T142A, and A287P had less than 10% of WT activity. POR variants A281T, P284L, and 
Y607C, lost around 75% of activity in CYP2C9 assays compared to WT POR. The POR variant Q153R retained 
50% of WT activity. Data are presented as mean ± SEM of three independent replicates. P values obtained by 
students T-test were as follows: A115V 8.08E-11; T142A 2.44E-10; Q153R 8.12E-09; A281T 1.43E-07; P284L 
1.06E-08; A287P 1.82E-11 and Y607C 1.21E-06. 
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Structural analysis of POR variants: The POR variants A115V, T142A, and Q153R, are 
located in the FMN binding domain of POR (Figure 1B). The POR variant A115V is predicted 
to be a structural variant which may alter redox partner interactions. The mutation T142A is 
located next to the FMN binding site of POR, and its mutation would affect FMN binding (Figure 
1B). The Q153 residue is located at the surface of POR and is predicted to have a role in the 
interactions of POR with its redox partners. The A281, P284 and A287 residues are located in 
the hinge region of the POR. The hinge region in POR provides conformational flexibility, and 
mutations in the hinge region would result in conformational changes that may alter the 
interaction of POR with its redox partners. 
 
 
Effect on CYP2C9 enzyme activity by POR genetic variations: The A115V, T142A, and 
A287P variants of POR showed 6.5–6.8 % CYP2C9 activity compared to WT (Figure 2). POR 
variants P284L had only 22% of WT activity while the A281T and Y607C variants showed 27% 
of WT activity. POR variant Q153R showed 56% of WT activity in CYP2C9 assays. 
 
 
 
Figure 3: CYP2C19 activity promoted by WT and variants of POR proteins. Activity with the WT POR was set as 
a hundred percent, and results are shown as a percentage of WT activity. POR variants A115V, T142A, P284L, 
and A287P, showed more than 50 loss of CYP2C19 activity compared to WT POR. The variant Y607C had 51% 
of WT activity, and A281T variant had 62% of WT activity. POR variant Q153R showed 83% of WT activity in 
CYP2C19 assays. Data are presented as mean ± SEM of three independent replicates. P values obtained by 
students T-test were as follows: A115V 3.7E-08; T142A 2.1E-07; Q153R 0.005; A281T 4.1E-05; P284L 1.05E-
07; A287P 3.4E-08 and Y607C 3.01E-09. 
 
Effect on CYP2C19 enzyme activity by POR genetic variations: The A115V, T142A, 
A281T, P284L A287P, and Y607C variants of POR showed 41.5 –61.5 % CYP2C9 activity 
(A115V 43%, T142A 42%, A281T 62%, P284L 45% and A287P 42%) compared to WT (Figure 
3). POR variant Q153R showed only a slight reduction in activity to 83% of WT POR (Figure 
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3). All variants had in general higher activities in CYP2C19 assays compared to CYP2C9 
assays. 
 
 
Effect on CYP3A5 enzyme activity by POR genetic variations: The A115V, T142A, and 
A287P and variants of POR showed 15.8–23.1 % CYP3A5 activity (A115V 18%, T142A 16%, 
A287P 23%) compared to WT (Figure 4). The P284L had 44% of WT activity while the 
Y607C variant retained 67% of WT POR activity in CYP3A5 assays (Figure 4). POR variant 
A281T had moderately increased values compared to WT POR in CYP3A5 assays (138 %) 
but the Q153R variant of POR enhanced the CYP3A5 activity around 4 folds (Figure 4).  
 
 
Figure 4: CYP3A5 activity promoted by WT and variants of POR proteins. Activity with the WT POR was set as 
a hundred percent, and results are shown as a percentage of WT activity.  In CYP3A5 assays POR variant A115V 
had 17% of WT activity while variant T142A had 16% of WT activity. POR variant A287P had 23% of WT activity 
and variant Y607C had 67% of WT activity. Two variants showed higher than WT activity with A281T showing 
136% of WT activity and Q153R showed 391% of WT activity in CYP3A5 assays. Data are presented as mean ± 
SEM of three independent replicates. P values obtained by students T-test were as follows: A115V 9.9E-13; 
T142A 1.28E-08; Q153R 1.24E-05; A281T 0.0024; P284L 7.26E-05; A287P 2.25E-08 and Y607C 0.0024. 
 
Discussion 
 
Here we studied the effects on drug metabolism and toxicology caused by POR gene mutations 
identified as potentially disease-causing variations. We selected the POR gene variants based 
on the sequencing data available from the 1000 Genome Project and other large sequencing 
studies [13]. Our earlier studies on POR variants indicate that there may be considerable 
differences in the effects of individual POR variants on the activities of different redox partners. 
While most POR variants have been studied for effects on steroid metabolizing enzymes like 
CYP17A1 and CYP19A1, there are few studies that have examined the role of POR on drug 
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metabolizing enzymes. We determined the enzymatic activities of three drug and xenobiotic 
metabolizing cytochromes P450 promoted by WT and the population genetic variants of POR. 
POR variant A115V earlier suspected as a polymorphism [27,32,42] inhibited all three 
cytochrome P450 activities severely, in agreement with its effect on CYP19A1 [43]. The A287P 
variant, which is the most common POR mutation found in patients of European origin 
[12,13,27,45], showed severe loss of activities in CYP2C9 and CYP3A5 assays which has 
important consequences for monitoring and treatment of patients [34,40].  
 
Interestingly, POR variant Q153R showed a reduction of 20-50 activities with CYP2C9 and 
CYP2C19 but had a 400% increased activity with CYP3A5. The severe effects of A115V, 
T142A, and can be explained due to their proximity to the FMN binding site of POR that has a 
vital role in protein-protein interaction. The POR variant Q153R is located at the surface and 
considering its variable effects on different partner proteins; it is likely to have a role in the 
interaction with redox partners of POR. POR Variants P284L and Y607C inhibited activities of 
all P450 proteins tested. The A281T POR variant had less activity than the WT with CYP2C9 
and CYP2C19 but showed slightly increased activity with CYP3A5. These results showed that 
POR variants have a diversity of possible effects depending on their redox partners. 
 
These results indicate that detailed knowledge about the effects of POR genetic variations is 
necessary for correct diagnosis and treatment options for persons with POR deficiency and the 
role of POR in the alterations in drug metabolism needs to be addressed. Changes in drug and 
steroid metabolism due to genetic variations can be addressed using personalized metabolic 
profiling and supplementation using modified dosages of drugs, steroids, or co-factors 
[14,24,41,46]. Several drugs, including the organ transplant drug tacrolimus, have narrow 
therapeutic ranges, and severe loss of CYP3A5 activity due to mutations in POR requires 
considering POR variations as modifiers of drug metabolism in addition to cytochrome P450 
variant alleles.   
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